- Home
- NTCL vs CDXS Comparison
NTCL vs CDXS Comparison
Compare NTCL & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTCL
- CDXS
- Stock Information
- Founded
- NTCL 2003
- CDXS 2002
- Country
- NTCL China
- CDXS United States
- Employees
- NTCL N/A
- CDXS N/A
- Industry
- NTCL
- CDXS Major Chemicals
- Sector
- NTCL
- CDXS Industrials
- Exchange
- NTCL NYSE
- CDXS Nasdaq
- Market Cap
- NTCL 193.8M
- CDXS 201.3M
- IPO Year
- NTCL 2024
- CDXS 2010
- Fundamental
- Price
- NTCL $3.50
- CDXS $2.25
- Analyst Decision
- NTCL
- CDXS Buy
- Analyst Count
- NTCL 0
- CDXS 2
- Target Price
- NTCL N/A
- CDXS $11.00
- AVG Volume (30 Days)
- NTCL 1.3M
- CDXS 1.0M
- Earning Date
- NTCL 01-01-0001
- CDXS 05-14-2025
- Dividend Yield
- NTCL N/A
- CDXS N/A
- EPS Growth
- NTCL N/A
- CDXS N/A
- EPS
- NTCL N/A
- CDXS N/A
- Revenue
- NTCL $10,101,647.00
- CDXS $49,815,000.00
- Revenue This Year
- NTCL N/A
- CDXS $2.41
- Revenue Next Year
- NTCL N/A
- CDXS $34.28
- P/E Ratio
- NTCL N/A
- CDXS N/A
- Revenue Growth
- NTCL N/A
- CDXS N/A
- 52 Week Low
- NTCL $2.90
- CDXS $1.90
- 52 Week High
- NTCL $51.80
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- NTCL N/A
- CDXS 42.74
- Support Level
- NTCL N/A
- CDXS $2.30
- Resistance Level
- NTCL N/A
- CDXS $2.56
- Average True Range (ATR)
- NTCL 0.00
- CDXS 0.20
- MACD
- NTCL 0.00
- CDXS -0.02
- Stochastic Oscillator
- NTCL 0.00
- CDXS 40.54
About NTCL NETCLASS TECHNOLOGY INC
Netclass Technology Inc is a business-to-business smart education specialist, providing IT solutions to schools, training institutions, corporations, public agencies and other institutions or corporate customers. It offers SaaS subscription service and application development. The solution's modules include teaching management, campus management, online teaching, online examination, epidemic prevention and control, education credit blockchain system, and lecturer evaluation services.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.